Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question What Are the New Weight Loss Medications? NowPatient
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols